

Table SI. Clinical characteristics of patients with advanced lung adenocarcinoma receiving either chemotherapy (n=39) or apatinib plus chemotherapy (n=23) as first-line treatment.

Characteristics	Chemotherapy, n (%)	Apatinib plus chemotherapy, n (%)	P-value
Mean age, years	59.9±9.4	55.9±8.8	0.101
Age, years			0.100
<60	17 (43.6)	15 (65.2)	
≥60	22 (56.4)	8 (34.8)	
Sex			0.168
Female	17 (43.6)	6 (26.1)	
Male	22 (56.4)	17 (73.9)	
Smoking history			0.946
No	20 (51.3)	12 (52.2)	
Yes	19 (48.7)	11 (47.8)	
ECOG-PS score			0.673
0	16 (41.0)	11 (47.8)	
1	22 (56.4)	12 (52.2)	
2	1 (2.6)	0 (0.0)	
TNM stage			0.331
IIIB/C	13 (33.3)	5 (21.7)	
IV	26 (66.7)	18 (78.3)	
Bone metastasis			0.454
No	35 (89.7)	19 (82.6)	
Yes	4 (10.3)	4 (17.4)	
Brain metastasis			1.000
No	33 (84.6)	19 (82.6)	
Yes	6 (15.4)	4 (17.4)	

Data are presented as mean ± standard deviation. ECOG PS, Eastern Cooperative Oncology Group-Performance Status; TNM, tumor-node-metastasis.

Table SII. Subgroup analyses based on chemotherapy regimens.

Regimen	Chemotherapy	Apatinib plus chemotherapy	P-value
Docetaxel			
Assessed patients	31	34	
ORR	10 (32.3)	15 (44.1)	0.326
DCR	24 (77.4)	28 (82.4)	0.619
PFS, months	7.7 (5.7-9.7)	11.3 (9.1-13.5)	0.069 ^a
OS, months	14.8 (8.6-21.0)	Not reached	0.025 ^a
TP			
Assessed patients	16	8	
ORR	6 (37.5)	5 (62.5)	0.247
DCR	12 (75.0)	8 (100.0)	0.121
PFS, months	8.8 (0.0-19.1)	14.2 (12.7-15.7)	0.157 ^a
OS, months	21.7 (10.8-32.6)	Not reached	0.263 ^a
AP			
Assessed patients	12	8	
ORR	4 (33.3)	7 (87.5)	0.017
DCR	8 (66.7)	8 (100.0)	0.068
PFS, months	7.9 (0.0-16.0)	17.1 (11.3-22.9)	0.022 ^a
OS, months	17.0 (15.5-18.5)	23.1 (20.6-25.6)	0.143 ^a
DP			
Assessed patients	12	7	
ORR	5 (41.7)	5 (71.4)	0.210
DCR	12 (100.0)	7 (100.0)	1.000
PFS, months	11.0 (5.9-16.1)	22.4 (not assessed)	0.152 ^a
OS, months	Not assessed	Not assessed	0.071 ^a
Pemetrexed			
Assessed patients	9	8	
ORR	4 (44.4)	3 (37.5)	1.000
DCR	7 (77.8)	7 (87.5)	1.000
PFS, months	7.5 (7.2-7.8)	13.3 (8.7-17.9)	0.017 ^a
OS, months	14.4 (11.8-17.0)	21.0 (11.5-30.5)	0.051 ^a

Data are presented as median (95% CI). ^aP-values were assessed based on overall differences in PFS or OS between the two groups using Kaplan-Meier curves and the log-rank test. ORR, overall response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; TP, paclitaxel plus platinum; AP, pemetrexed plus platinum; DP, docetaxel plus platinum.